ANB033 is a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2

IND filing to support clinical development of ANB033 anticipated in first half of 2024

Anti-CD122 antagonist reduces pathogenic TRM and NK Cells

CD122 is a shared beta subunit of the receptors for IL-15 and IL-2
CD122 antagonist mAb will potently inhibit IL-2 and IL-15 biology

Both IL-15 and IL-2 mediate:

  • Proliferation and survival of NK cells and subsets of T cells
  • Inflammatory cytokine secretion (IFNγ) during T cell activation

IL-15 mediates survival of TRM cells

High affinity antagonist antibody reduces pathogenic cells by preferentially inhibiting the lower affinity dimeric receptor complex

  • Spares Tregs which express higher affinity IL-2 trimeric receptor complex

Targeted reduction of TRM cells may potentially drive durable response